非一线抗结核药物耐药机制及耐药性诊断研究进展

doi:10.16288/j.yczz.16-138

[an error occurred while processing this directive]

Hereditas(Beijing) ›› 2016, Vol. 38 ›› Issue (10): 928-939.doi: 10.16288/j.yczz.16-138

• Reviews • Previous Articles Next Articles

Progress in resistance mechanisms and diagnosis of non-first line anti-TB drugs

Yang Liu^{1, 2}, Bangxing Wang¹, Zhiyong Liu¹, Yi Han¹, Yaoju Tan³, Xinjie Li³, Jianxiong Liu³, Shouyong Tan³, Tianyu Zhang¹

1. State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), Guangzhou 510530, China;
2. Institute of Health Sciences, Anhui University, Hefei 230601, China;
3. Research Division on Tuberculosis, National Key Laboratory on Respiratory Diseases, Guangzhou Chest Hospital, Guangzhou 510095, China

Received:2016-04-20 Revised:2016-07-14 Online:2016-10-20 Published:2016-10-20
Supported by:
[Supported by the National Natural Science Foundation of China ( No; 81572037),Guangzhou Municipal Clinical Medical Center Program (Nos; 155700012, 201508020248) and the Open Project Grant from the State Key Lab of Respiratory Disease (No; 2014SKLRD-006)]

Abstract

Abstract: Tuberculosis (TB) is one of the three major infectious diseases in China and all over the world. In 2014, for the first time, TB killed more people than HIV did. Non-first line anti-TB drugs are used as main drugs in the treatment of MDR-TB. However, MDR-TB can gradually develop as extensively drug-resistant TB (XDR-TB) because of poor diagnosis, the unreasonable treatment, poor medical conditions and so on. The death rate of XDR-TB is close to lung cancer. Research on the mechanism of drug resistance of Mycobacterium tuberculosis has turned to non first-line anti-TB drugs: second and third line drugs and some new anti-TB drugs in development. In this review, we summarized the drug resistance mechanisms of the common non-first line anti-TB drugs. Most of drug resistant TB patients can’t get timely diagnosis and correct treatment. So at the end of this article, we also summarized the common methods to diagnose drug-resistant TB.

Key words: tuberculosis, Mycobacterium tuberculosis, drug resistance, diagnosis

Yang Liu, Bangxing Wang, Zhiyong Liu, Yi Han, Yaoju Tan, Xinjie Li, Jianxiong Liu, Shouyong Tan, Tianyu Zhang. Progress in resistance mechanisms and diagnosis of non-first line anti-TB drugs[J]. Hereditas(Beijing), 2016, 38(10): 928-939.

References

[1] World Health Organization. Global tuberculosis report 2015. Geneva: World Health Organization, 2015.
[2] Technical Guidance Group of the Fifth National TB Epidemiological Survey, the Office of the Fifth National TB Epidemiological Survey. The fifth national tuberculosis epidemiological survey in 2010. Chin J Antituberc , 2012, 34(8): 485-508. 全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012, 34(8): 485-508.
[3] Van Rie A, Enarson D. XDR tuberculosis: an indicator of public-health negligence. Lancet , 2006, 368(9547): 1554- 1556.
[4] Iseman MD. Evolution of drug-resistant tuberculosis: A tale of two species. Proc Natl Acad Sci USA , 1994, 91(7): 2428-2429.
[5] Zhao YL, Xu SF, Wang LX, Chin DP, Wang SF, Jiang GL, Xia H, Zhou Y, Li Q, Ou XC, Pang Y, Song YY, Zhao B, Zhang HT, He GX, Guo J, Wang Y. National survey of drug-resistant tuberculosis in China. N Engl J Med , 2012, 366(23): 2161-2170.
[6] Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill , 2007, 12(5): E070517.
[7] Klopper M, Warren RM, Hayes C, van Pittius NCG, Streicher EM, Müller B, Sirgel FA, Chabula-Nxiweni M, Hoosain E, Coetzee G, van Helden PD, Victor TC, Trollip AP. Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis , 2013, 19(3): 449-455.
[8] Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis , 2012, 54(4): 579-581.
[9] ZumLa A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov , 2013, 12(5): 388-404.
[10] Wong SY, Lee JS, Kwak HK, Via LE, Boshoff HIM, Barry CE. Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis . Antimicrob Agents Chemother , 2011, 55(6): 2515-2522.
[11] Gao Q, Huang HH. Update on antimicrobial resistance in Clostridium difficile . Hereditas ( Beijing ), 2015, 37(5): 458-464. 高琼, 黄海辉. 艰难梭菌耐药性及耐药机制研究进展. 遗传, 2015, 37(5): 458-464.
[12] Long QX, He Y, Xie JP. The molecular physiological and genetic mechanisms underlying the superb efficacy of quinolones. Acta Pharm Sin , 2012, 47(8): 969-977. 龙泉鑫, 何颖, 谢建平. 喹诺酮类药物作用的生理和遗传的分子机制. 药学学报, 2012, 47(8): 969-977.
[13] Zhang S, Chen JZ, Cui P, Shi WL, Zhang WH, Zhang Y. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis . J Antimicrob Chemother , 2015, 70(9): 2507-2510.
[14] Pantel A, Petrella S, Veziris N, Brossier F, Bastian S, Jarlier V, Mayer C, Aubry A. Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M . tuberculosis . Antimicrob Agents Chemother , 2012, 56(4): 1990-1996.
[15] Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs , 2001, 61(1): 9-18.
[16] Bozeman L, Burman W, Metchock B, Welch L, Weiner M, Consortium TT. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis , 2005, 40(3): 386-391.
[17] Wang HY, Wang Y, Yu CB, Zuo Y, Wang JL, Liu ZM. Study of the status of drug resistant tuberculosis in 12 counties in Shandong. Prev Med Trib , 2008, 14(12): 1075-1076, 1080. 王海英, 王燕, 于春宝, 左云, 王俊玲, 刘志敏. 2004~ 2007年山东省部分结核分枝杆菌耐药情况检测分析. 预防医学论坛, 2008, 14(12): 1075-1076, 1080.
[18] Zhang GL, Du CM, Takuya K, Wang W, Shi RR. China-Japan cooperation project on second line tuberculosis drug resistance survey in Henan Province. J Med Forum , 2005, 26(19): 14-16. 张国龙, 杜长梅, 苍泽卓也, 池田雄史, 王伟, 石瑞如. 中日合作对河南省结核菌二线药物耐药监测研究. 医药论坛杂志, 2005, 26(19): 14-16.
[19] Pan XQ, Xu DF, Wang DP, Chai H, Yu SQ, Wang Q. Drug resistance of 251 strains of multidrug resistant Mycobacterium tuberculosis to second-line drugs. Anhui Med Pharm J , 2012, 16(9): 1339-1340. 潘学琴, 徐东方, 王东萍,

Metrics

Comments

www.chinagene.cn
备案号：京ICP备09063187号

Progress in resistance mechanisms and diagnosis of non-first line anti-TB drugs

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Beiping Zeng, Hongen Xu, Lu Mao, Wenxue Tang. Molecular diagnosis of hereditary deafness and application of stepwise testing strategy [J]. Hereditas(Beijing), 2023, 45(1): 29-41.
[2]	Min Shen, Yong Gu, Changjiang Ying, Mei Zhang, Tao Yang, Yang Chen. Diagnosis, treatment and genetic analysis of a case with fibrocalculous pancreatic diabetes [J]. Hereditas(Beijing), 2022, 44(11): 1079-1086.
[3]	Jiaqi Liang, Chang Liu, Wenxiang Zhang, Siyu Chen. Interaction between hepatokines and metabolic diseases [J]. Hereditas(Beijing), 2022, 44(10): 853-866.
[4]	Yanni Kou, Shan Cen, Xiaoyu Li. Research and application on LINE-1 in diagnosis and treatment of tumorigenesis [J]. Hereditas(Beijing), 2021, 43(6): 571-579.
[5]	Huxing Chen, Lei Xu, Jing Li, Zheng Guo, Lu Ao. The development of a general drug resistance score model based on MIC₅₀ related gene pairs in colorectal cancer cell lines [J]. Hereditas(Beijing), 2020, 42(6): 577-585.
[6]	Chenxi Zhou, Mo Li, Cong Huai, Lin He, Shengying Qin. Study on hereditary susceptibility genetic markers to anti-tuberculosis drug induced liver injury in Chinese population [J]. Hereditas(Beijing), 2020, 42(4): 374-379.
[7]	Xiaoqi Zhao, Ying Ao, Haiyun Chen, Hui Wang. The role of miRNA in kidney development [J]. Hereditas(Beijing), 2020, 42(11): 1062-1072.
[8]	Liyuan Zhang, Fujing Huang, Junqi Xu, Zhen Gong, Jianping Xie. Acid-resistant genes in Mycobacterium tuberculosis and the underlying regulatory network [J]. Hereditas(Beijing), 2018, 40(7): 546-560.
[9]	Ying Huang,Qi Liu,Lianjiang Chi,Chengmin Shi,Zhen Wu,Min Hu,Hong Shi,Hua Chen. Application of BIG-Annotator in the genome sequencing data functional annotation and genetic diagnosis [J]. Hereditas(Beijing), 2018, 40(11): 1015-1023.
[10]	Fulin Liu, Jin Zhou, Wei Zhang, Hui Wang, . Epigenetic regulation and related diseases during placental development [J]. Hereditas(Beijing), 2017, 39(4): 263-275.
[11]	Yongxin Zou,Yaoqin Gong. Aberrant RNA splicing as the molecular basis of some pathogenic variants [J]. Hereditas(Beijing), 2017, 39(3): 200-207.
[12]	Wei Gao, Wei Shi, Changhui Chen, Denian Wen, Jin Tian, Kaihu Yao. Epidemiological study on the penicillin resistance of clinical Streptococcus pneumoniae isolates identified as the common sequence types [J]. Hereditas(Beijing), 2016, 38(10): 940-947.
[13]	Yujiao Zhang, Xiaojing Li, Kaixia Mi. Mechanisms of fluoroquinolone resistance in Mycobacterium tuberculosis [J]. Hereditas(Beijing), 2016, 38(10): 918-927.
[14]	Ting Wang, Weiwei Jiao, Adong Shen. Progress on mechanism of ethambutol resistance in Mycobacterium Tuberculosis [J]. Hereditas(Beijing), 2016, 38(10): 910-917.
[15]	Yufan Chen, Shiyin Liu, Zhibin Liang, Mingfa Lv, Jianuan Zhou, Lianhui Zhang. Quorum sensing and microbial drug resistance [J]. Hereditas(Beijing), 2016, 38(10): 881-893.